AMWatch

Venturefond skyder millioner i svensk biotekselskab

Stockholm-selskabet Modus Therapeutics har rejst trecifret millionbeløb i en finansieringsrunde anført af den svenske venturefond Healthcap.

En illustration af blodsygdommen seglcelleanæmi. | Photo: Colourbox

Biotekselskabet Modus Therapeutics har endnu en gang hentet et stort millionbeløb til udviklingen af hovedkandidaten, fase 2-midlet sevuparin.

I en ny finansieringsrunde har selskabet med base i den svenske hovedstad Stockholm således rejst 140 mio. svenske kroner, svarende til ca. 101 mio. danske kroner, til den videre udvikling af lægemiddelkandidaten, der udvikles som en subkutan behandling af den arvelige blodsygdom seglcellesygdom.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Nasdaq reports record year in Europe

In 2021, the number of new equity listings on the Nasdaq exchange in Copenhagen broke the old record set in 2007, and in Stockholm, the exchange recorded its highest-ever number of new listings. Nasdaq also had increasing trading volumes last year.

Related articles

Latest news

Jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch